Eli Lilly and Company (LLY)

Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

3 Growth Stocks to Invest $1,000 Right Now

Those who succeed at building wealth in the stock market often do so by buying and holding stakes in companies that have the ability to expand steadily over time. Such companies can frequently be found in the technology and healthcare sectors -- two sources of innovations that sometimes reshape our lives.

Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth

Eli Lilly's valuation has compressed significantly from last year's highs, despite fundamentals improving faster than its share price. Industry-leading incretin treatments (Mounjaro, Zepbound) are driving rapid revenue growth, with market share gains over Novo Nordisk. Capacity expansion, U.S.-based manufacturing, and price reductions are improving accessibility while sustaining margins.

LLY Stock Set For A 20% Breakout?

Eli Lilly stock (NYSE: LLY) should be on your radar. Here's why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly.

A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products puts over 50% of its free cash flow at risk, despite ongoing U.S. manufacturing expansion. Sanofi's high-margin Dupixent and AZN's broad U.S. portfolio are also vulnerable, though both are investing in U.S. production to seek exemptions.

LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy

Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

US FDA approves Eli Lilly's therapy for metastatic breast cancer

Eli Lilly said on Thursday that the U.S. Food and Drug Administration has approved its therapy for the treatment of metastatic breast cancer in patients whose disease progressed after at least one line of endocrine therapy.

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC INDIANAPOLIS , Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), …

Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Eli Lilly and Company (NYSE:LLY ) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of Investor Relations Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

Eli Lilly: Buying The Dip With Confidence

Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing, superior clinical trial results, and AI-driven drug discovery reinforce its competitive edge and future revenue potential. Valuation is set to improve as earnings are projected to surge, making LLY's current high P/E attractive for long-term investors seeking growth.

LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?

Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.

2 stocks to reach $1 trillion market cap in 2026

Amid the ongoing United States stock market rally, several equities have experienced increased buying pressure, pushing their valuations closer to the coveted $1 trillion market capitalization mark.

Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas

The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.

Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant

Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday.

Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs

Eli Lilly said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of small molecule drugs, including its closely watched experimental obesity pill. It is the second in a string of four new planned U.S. plants by the drugmaker, which will all begin making medicine within five years.

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas

The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines Company plans to create 4,615 manufacturing and construction jobs INDIANAPOLIS , Sept. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas.

Mounjaro, Ozempic: Obesity market shifting to portfolio play as GLP-1 innovation peaks, says leading bank

Goldman Sachs analysts say the obesity drug market is entering a new phase where breadth of treatment options, rather than reliance on a single blockbuster, will determine long-term winners. Wrapping up last week's European Association for the Study of Diabetes (EASD) meeting, the bank highlighted three key trends.

This Unstoppable Healthcare Stock Just Made a Move in AI: Time to Buy?

Recent breakthroughs in artificial intelligence (AI) are producing tangible results, and not just in the tech industry, although companies in that sector tend to dominate the AI headlines. Even in healthcare, the technology can help boost productivity and efficiency.

Eli Lilly's Oral GLP-1 Breakthrough Could Change Everything

Eli Lilly and Company NYSE: LLY has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, which is transforming the management of type 2 diabetes and the obesity market.

LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms

Eli Lilly and Company's hot streak of obesity and type 2 diabetes readouts ended in early August when we saw underwhelming top-line phase 3 results of orforglipron in obesity patients. Orforglipron looks inferior to oral semaglutide 25mg across trials on weight loss efficacy, but it also beats oral semaglutide 7mg and 14mg in a head-to-head trial. I still see orforglipron as a viable product but am less positive on it after the lower-than-expected efficacy in patients with obesity.

LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?

Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.

Data on Eli Lilly's Weight Loss Pill Hasn't Thrilled Investors. New Updates Are Complicating the Picture.

3 Stocks Insiders Are Buying Non-Stop

Insider buying is one of the few market signals that does not hide behind algorithms or price targets.

Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival

The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk's oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.

GLP-1 drugs could save millions of lives — and spark a pension crisis

GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.

Lilly says its experimental GLP-1 pill better than Novo's Rybelsus in diabetes study

Eli Lilly on Wednesday said its experimental pill led to more weight loss and better control of blood sugar in patients with diabetes than oral semaglutide, the active ingredient in Danish rival Novo Nordisk's diabetes and weight-loss medicines.

Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial

Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill, orforglipron, was superior at the trial's main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk's oral semaglutide, and helped patients lose more weight.

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial

For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs.